Sleep quality is diminished in patients with PsA. Sleep disturbance is particularly associated with generalized pain, anxiety, enthesitis and levels of CRP and ESR in patients carrying the diagnosis of PsA.

The aim of the present study was to emphasize the collagen turnover in 2 of the most common chronic inflammatory rheumatic diseases by evaluating serum prolidase activity (SPA) in ankylosing spondylitis (AS) and rheumatoid arthritis (RA). 30 patients who met the modified New York Criteria for the classification of AS, 29 patients who met the 2010 Rheumatoid Arthritis Classification Criteria for the classification of RA, and 31 healthy controls were enrolled in the study. Serum samples of the patients and the controls were collected and SPA was measured by a spectrophotometric method. The comparison of the SPA in these 3 groups was statistically examined. In both patient groups, the SPA was lower than in the control group. SPA in patients with AS was statistically significantly lower than in the control and RA groups (P < 0.001/P = 0.002). No statistically significant difference was found between the RA and the control groups (P = 0.891). In conclusion, lower SPA is presumably associated with decreased collagen turnover and fibrosis, leading to decreased physical functions in both chronic inflammatory musculoskeletal diseases.

HMGB1 protein might be a good laboratory-sourced candidate for the assessment of functional status and disease severity in patients with FM.

Background High mobility group box 1 protein (HMGB1) is a proinflammatory cytokine. Previous studies have suggested that HMGB1 can play an important role in the pathogenesis of many rheumatic diseases. [1-3] Objectives The aim of the present study was to investigate the serum levels of high mobility group box 1 protein in patients with fibromyalgia (FM) and its association with quality of life, psychological and functional status in these patients. Methods Twenty-nine patients who met the 1990 American College of Rheumatology (ACR) criteria for the classification of FM and twenty-nine healthy controls (HC) were enrolled to the study. Serum samples of patients and HC were collected and HMGB1 levels were measured by enzyme-linked immunosorbent assay (ELISA). Fibromyalgia Impact Questionnaire (FIQ) was used to assess disease severity and functional status of patients with FM. The quality of life of the all subjects were assessed by Nottingham Health Profile (NHP) and depression and anxiety symptoms were evaluated by using the Hospital Anxiety and Depression Scale (HADS). Results HMGB1 protein levels were positively correlated with FIQ scores in patients with FM (p=0.002). However mean serum HMGB1 levels in patients with FM (0.711±0.391 ng/ml) were higher than HC (0.651±0.390 ng/ml), no significant difference was seen between two groups (p=0.474). Conclusions HMGB1 protein may be a good laboratory sourced candidate for the assessment of functional status and disease severity in patients with FM. References -Taniguchi N, Kawahara K, Yone K et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003; 48, 971-981 -Chun yun ma Ma C, Jiao Y, Zhang J et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 2012; 32, 395-402 -Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 2006; 54, 2289-2294. Disclosure of Interest None Declared